Forte Biosciences, Inc.
FBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Forte Biosciences, Inc. (FBRX) is listed under Biotechnology. The $390.5M market capitalization puts FBRX squarely in small-cap range for its industry. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
Market Cap
$390.5M
Beta
3.00
P/E (TTM)
—
P/E (Fwd)
-4.60
EPS (TTM)
$-4.58
EPS (Fwd)
$-4.14
ROE
-188.4%
ROA
-83.9%
Cash
$58.2M
Total Debt
$0
Free CF
-$31.2M
52W Change
116.0%
Annual Financials
Cash vs Debt
Forte Biosciences, Inc. reports $58.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$31.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -188.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 3.00 means FBRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Forte Biosciences, Inc.'s trajectory.